To determine whether the effects of combined BMS-1166 and BEZ235 block the PI3K/mTOR and MAPK pathway activation in CRC cells by suppressing PD1 binding to PD-L1, we detected the levels of PD-L1 and key molecules of PI3K/mTOR and MAPK signaling after 24-h drug treatment by western blot. The gene discussed is MTOR; the disease is colorectal carcinoma.